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g-secretase directly sheds the survival receptor
BCMA from plasma cells
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Survival of plasma cells is regulated by B-cell maturation antigen (BCMA), a membrane-bound
receptor activated by its agonist ligands BAFF and APRIL. Here we report that g-secretase
directly cleaves BCMA, without prior truncation by another protease. This direct shedding is
facilitated by the short length of BCMA’s extracellular domain. In vitro, g-secretase reduces
BCMA-mediated NF-kB activation. In addition, g-secretase releases soluble BCMA (sBCMA)
that acts as a decoy neutralizing APRIL. In vivo, inhibition of g-secretase enhances BCMA
surface expression in plasma cells and increases their number in the bone marrow.
Furthermore, in multiple sclerosis, sBCMA levels in spinal fluid are elevated and associated with
intracerebral IgG production; in systemic lupus erythematosus, sBCMA levels in serum are
elevated and correlate with disease activity. Together, shedding of BCMA by g-secretase
controls plasma cells in the bone marrow and yields a potential biomarker for B-cell
involvement in human autoimmune diseases.
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B
cells are of pathogenic relevance and serve as a therapeutic
target both in generalized immunopathological diseases
such as systemic lupus erythematosus (SLE), and in
organ-specific diseases such as multiple sclerosis (MS)1,2.
Activation and survival of B cells is largely regulated via the
BAFF–APRIL system that comprises three receptors (BAFF-R,
TACI and BCMA (B-cell maturation antigen)) and two ligands
(BAFF and APRIL)3. Membrane-bound BCMA (mBCMA) is
expressed on some activated B cells4 and Ig-secreting cells5,6; it
binds both BAFF and APRIL3. BCMA is essential for the
maintenance of long-lived plasma cells7,8, an effect mediated by
APRIL or BAFF9,10. These plasma cells produce IgG that protect
not only against pathogens but are also critically involved in
autoimmune diseases11,12. Further, mBCMA engagement on
activated B cells induces MHC class II, enhancing their ability to
present antigen4.
The BAFF–APRIL system is targeted for therapeutic interven-
tion. In SLE, where BAFF levels in the serum are elevated, an
antibody-binding BAFF is already approved13,14. On the other
hand, the recombinant soluble receptor atacicept, which targets
both BAFF and APRIL, unexpectedly worsened MS15, indicating
that essential features of this system are not fully understood.
Other clinical trials targeting the BAFF–APRIL system in
immunopathological disorders have been launched13,14.
We aimed at identifying features of humoral immunity that
might be altered in autoimmune diseases. Thereby, we found that
a soluble form of BCMA (sBCMA) is regularly detectable in
human blood. We then analysed sBCMA in human autoimmune
diseases. In MS, sBCMA was elevated in the cerebrospinal
fluid (CSF) and linked to local IgG production inside the brain.
In SLE, sBCMA was systemically elevated and associated with
disease activity. We went on to uncover the underlying
biochemical mechanism and found that BCMA was directly shed
by g-secretase, a ubiquitous intramembranous protease. Direct
shedding of a membrane protein without prior processing by
another protease is a novel function of g-secretase, which is best
known for processing of amyloid precursor protein (APP) in
Alzheimer’s disease and Notch16,17. To analyse the functional
relevance of this shedding in vivo, we treated mice with a
g-secretase inhibitor; this enhanced surface BCMA on plasma
cells and increased their number in the bone marrow. Thus,
shedding of BCMA via g-secretase is an immunoregulatory
mechanism limiting plasma cells.
Results
sBCMA shows local IgG production in MS and activity in SLE.
We found sBCMA as a regular component of human blood from
healthy subjects (Fig. 1a). In MS, sBCMA was elevated in the CSF,
but not in the blood (Fig. 1a,b). sBCMA levels in the plasma and
serum were very similar as seen in 14 controls (Supplementary
Fig. 1a). Levels of sBCMA in the CSF correlated strongly with
local IgG production in MS patients (Fig. 1c). This strong
correlation was confirmed in a second cohort of 25 MS patients
(Po0.0001, r¼ 0.80, Spearman rank correlation). Also in
neuroborreliosis, an infectious neuroinflammatory disease char-
acterized by chronic IgG production within the CNS, sBCMA
levels were increased and correlated with local IgG production
(Fig. 1b,c). In CSF from MS patients, there was a slight inverse
correlation of sBCMA with its high-affinity ligand APRIL
(r¼  0.35, P¼ 0.033, Spearman rank correlation), but
no association to the plasma level of sBCMA (r¼ 0.07,
P¼ 0.667, Spearman rank correlation). We analysed effects of
immunosuppressive treatment on sBCMA levels longitudinally in
two cohorts of MS patients. Natalizumab, which blocks entry of
lymphocytes into the CNS18 and local IgG production2, reduced
sBCMA in the CSF (Supplementary Fig. 1b). High-dose steroids
for treatment of acute relapses reduced serum sBCMA levels
transiently (Supplementary Fig.1c).
In SLE, serum levels of sBCMA were elevated as seen in an
untreated and in a treated cohort (Fig. 1d). Immunosuppressive
treatment of SLE patients reduced sBCMA levels (Fig. 1d). We
noted a strong correlation of serum sBCMA and disease activity
(Fig. 1e) and an inverse correlation with the paraclinical marker
complement factor 3 (Fig. 1f). There was a trend (P¼ 0.0767,
r¼ 0.23, Spearman rank correlation) for correlation between
anti-dsDNA titre and sBCMA in these SLE patients. Serum BAFF
levels were elevated in our SLE cohort (mean¼ 0.61±0.13 ng ml 1
in healthy controls; mean¼ 2.11±4.32 ng ml 1 in SLE patients,
P¼ 0.0004, Wilcoxon–Mann–Whithney test), and correlated with







































































































Figure 1 | sBCMA as a biomarker. (a) sBCMA plasma concentrations
were determined using ELISA in healthy controls (HC), patients with a
clinically isolated syndrome (CIS) or MS, or other neurological diseases
(OND). (b) sBCMA in the CSF was determined in patients with OND,
CIS/MS or neuroborreliosis (NB) (***Po0.001, Kruskal–Wallis test
followed by Dunn’s Multiple Comparison Test). (c) sBCMA in the CSF
correlated strongly with the intrathecal IgG production represented by the
IgG Index. This correlation was evident when all analysed CSF samples were
considered (Po0.0001, r¼0.85) and in the MS/CIS group (Po0.0001,
r¼0.77, Spearman rank correlation, CIS/MS n¼ 36; OND n¼ 20,
NB n¼ 5). (d) sBCMA in the serum was determined with ELISA in HC,
untreated (red) and treated (black) patients with SLE. sBCMA was elevated
in SLE patients and in the untreated SLE patients compared with the treated
patients (***Po0.001 and *Po0.05, Kruskal–Wallis test followed by
Dunn’s Multiple Comparison Test). (e) sBCMA in the serum of SLE patients
correlated strongly with disease activity quantified with SLE disease activity
index (SLEDAI; Po0.001; r¼0.54, Spearman correlation). (f) sBCMA in
the serum of SLE patients inversely correlated with the level of the
complement factor C3 (P¼0.0374, r¼ 0.29, Spearman correlation).
Bars represent means.
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BCMA is shed during differentiation to Ig-secreting cells. Since
mBCMA is known to be expressed on some activated B cells and
Ig-secreting cells5,6, we analysed the release of sBCMA by
primary human B cells. We applied two different protocols to
activate human primary B cells in order to differentiate them
towards Ig-secreting cells. First, purified blood-derived human
B cells were activated via CD40L and further differentiated to
Ig-secreting cells by adding interleukin (IL)-21 (ref. 5). While
human B cells activated via CD40L alone released low, but
detectable, levels of sBCMA, this was strongly enhanced by
addition of IL-21 (Fig. 2a). In the second primary B-cell culture
system we activated peripheral blood mononuclear cells (PBMC)
with the TLR7þ 8 ligand R848 and IL-2, which induces
differentiation of human memory B cells to Ig-secreting cells19.
Again, differentiation towards IgG-secreting cells was
accompanied by the appearance of sBCMA (Fig. 2b).
After activation with CD40Lþ IL-21, two B-cell populations,
CD19þCD38 and CD19þCD38þ , cells could be distin-
guished. We directly compared mBCMA and release of sBCMA
by these different B-cell subsets. While mBCMA was absent on
unstimulated B cells, CD19þCD38 cells weakly and CD19þ
CD38þ cells strongly expressed mBCMA (Fig. 2c). We sorted
CD38þ and CD38 cells, cultured them for another 24 h
without further stimulation and determined the amount of shed
sBCMA (Fig. 2d). This revealed a close correlation between
released sBCMA and surface expression of mBCMA (Fig. 2e).
The transcription of BCMA in these B-cell subsets was further





























































































































































Nt-MLQMA GQCSQ NEYFD SLLHA CIPCQ LRCSS NTPPL TCQRY CNASV TNSVK GTNAI LWTCL GLSLI ISLAV FVLMF LLRKI…
Figure 2 | sBCMA is released when B cells differentiate towards plasma cells and comprises the extracellular domain plus part of the
transmembranous region of BCMA. (a) Human purified B cells were activated for 5 days as indicated; IgG and sBCMA in the supernatant were quantified
using ELISA. Combined data of three independent experiments (mean±s.e.m., P¼0.0073, paired t-test). (b) PBMCs were stimulated with R848þ IL-2 for
7 days. IgG and sBCMA in the supernatant were quantified using ELISA. Combined data of three independent experiments (mean±s.e.m., P¼0.0227,
paired t-test). (c–e) Human purified B cells were stimulated with CD40Lþ IL-21. (c) surface BCMA was measured using flow cytometry on unstimulated B
cells, CD19þCD38 cells and CD19þCD38þ cells. (d) Sorted CD38þ and CD38 cells were cultured for another 24 h and the amount of shed sBCMA
was measured using ELISA, combined data of two independent experiments. (e) Correlation between sBCMA release and surface expression of BCMA for
a single replicate. (f,g) sBCMA was immunoprecipitated from supernatant of plasmacytoma cells (f, lanes 1, 2), serum (f, lane 3) and from supernatant of
human purified B cells cultured with CD40L plus IL-21 (f, lane 4) with anti-BCMA monoclonal antibodies (mAbs) A7D12.2 (f, lanes 1 and 4) or C12A3.2
(f, lane 2) or goat-anti-BCMA (f, lane 3). Western blot analysis for BCMA (f) and silver staining of sBCMA immunoprecipitated from plasmacytoma
supernatant (g) was performed. (h) The band at 6 kDa (from g) and sBCMA obtained using immunoprecipitation were analysed with mass spectrometry.
The aa sequences of BCMA and peptides identified after tryptic (blue) or chymotryptic (red) digestion are shown. No peptide was detected with a
C-terminal aa that was not a site for either tryptic or chymotryptic cleavage, indicating that the precise cleavage site of g-secretase within the membrane
needs to be identified.
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cells reached 15.9±5.2% peptidyl-prolyl isomerase A (PPIA),
while BCMA expression in the CD38 cells subset accounted for
2.5±1.3% PPIA (mean±s.e.m. of three independent replicates).
Thus, in these B-cell subsets BCMA surface expression reflected
BCMA transcription.
We also analysed BCMA shedding in tumour cell lines and
transfectants. The human plasmacytoma cell line JK-6L sponta-
neously shed sBCMA (Supplementary Fig. 2a). In BCMA-
transfected HeLa cells surface expression of mBCMA was
accompanied by release of sBCMA (157±6 ng ml 1) without
requiring any further stimulus. HeLa cells did not secrete
detectable amounts of APRIL or BAFF, neither spontaneously
nor after transfection with BCMA or an empty vector. Together,
our observations with primary human B-cell cultures, plasmacy-
toma cells and BCMA-transfected cells indicate that release of
sBCMA is a direct consequence of surface expression of mBCMA;
it does not require additional stimulation or ligand binding.
sBCMA comprises extracellular and intramembranous part.
sBCMA was isolated by immunoprecipitation from the super-
natant of primary Ig-secreting cells, plasmacytoma cells or serum;
in all these sources, sBCMA had a molecular weight (MW) of
B6 kDa as seen using western blot analysis (Fig. 2f). This size was
confirmed when silver staining was applied to detect material
obtained by immunoprecipitation with anti-BCMA from the
supernatant of plasmacytoma cells (Fig. 2g). This corresponds to
the extracellular part of BCMA (54 amino acid (aa), calculated
MW 5.8 kDa). Unexpectedly, mass spectrometry revealed that
sBCMA comprised not only the complete extracellular domain
with an intact N terminus, but also part of the transmembrane
region (Fig. 2h). This indicated that it was released by an intra-
membranous protease.
c-secretase inhibitors block BCMA shedding from B cells. Since
mBCMA is a type-I oriented transmembrane protein with an
extracellular N terminus, g-secretase was a candidate for its
intramembranous cleavage. We applied the g-secretase inhibitor
DAPT and compared it with the metalloprotease inhibitor TAPI-
1, which reduces the shedding of other TNFR-SF members. We
activated human B cells either via CD40Lþ IL-21 (Fig. 3a,b) or
via R848þ IL-2 (Fig. 3c,d), and used both fluorescence-activated
cell sorting (FACS) and enzyme-linked immunosorbent assay
(ELISA) as read-out systems to quantify mBCMA and sBCMA.
DAPT blocked the release of sBCMA even at low concentrations,
while TAPI-1 had little or no effect (Fig. 3a,c). After CD40Lþ IL-
21 application, a high surface expression of mBCMA was noted in
the CD27þ þCD38þ subset (Fig. 3b), previously classified as late
plasmablasts20. DAPT enhanced surface expression of mBCMA
in these cells, while TAPI-I had little or no effect (Fig. 3b). When
human PBMCs were activated with R848þ IL-2, B20% of the
cells were CD19þCD38þ after 7 days (Fig. 3d). These cells
strongly expressed mBCMA on their surface and this was greatly
enhanced by the g-secretase inhibitor DAPT; again, TAPI-I had
little effect (Fig. 3d). Similar to primary human B cells, we
observed differential effects of DAPT and TAPI-1 on the release
of sBCMA and surface expression of mBCMA on human
plasmacytoma cells (Supplementary Fig. 2a,b).
Further, we compared the effect of transition (LY-411575-I and
LY685,458) and non-transition state (DAPT and RO4929097)
inhibitors of the g-secretase on BCMA shedding from human B
cells. Human PBMCs were first stimulated with R848þ IL2 for 7
days, and then CD19þ B cells were positively selected and
cultured overnight in the absence of these g-secretase inhibitors.
We found that RO4929097, LY-411575-I and LY685,458 had
similar effects as DAPT on the shedding of mBCMA as seen with
both read-out systems, FACS and ELISA (Supplementary Fig. 3).
c-secretase directly sheds BCMA. Presenilin (PS)1 or PS2 is the
catalytical component of the g-secretase complex14,15. To finally
prove that sBCMA is released by g-secretase, we switched from B
cells to mouse embryonic fibroblasts (MEF) deficient for both PS1
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Figure 3 | c-secretase inhibitor DAPT reduces release of sBCMA and
enhances surface expression of BCMA on activated human B cell.
(a,b) Human B cells were differentiated into Ig-secreting cells via
CD40Lþ IL-21. (a) Release of sBCMA on treatment with DAPT or TAPI-1
was measured using ELISA. sBCMA release was normalized to the amount
of sBCMA shed under vehicle conditions, which was set as 100%.
Combined data of three independent experiments (mean±s.e.m.).
(b) These activated primary human B cells were subgrouped on the basis of
expression of CD27 and CD38. A high surface expression of BCMA was
seen on the CD27þ þCD38þ subset. Surface expression of BCMA was
enhanced using DAPT treatment (1mM), while TAPI-I (50mM) had little
effect. (c,d) Human PBMCs were stimulated with R848þ IL-2 for 7 days.
(c) Release of sBCMA on treatment with DAPT or TAPI-1 was measured
using ELISA. sBCMA release was normalized to the amount of sBCMA shed
under vehicle conditions, which was set as 100%. Combined data of three
independent experiments (mean±s.e.m.). (d) High surface expression of
BCMA was seen on the CD19þCD38þ subset; this was further enhanced
by DAPT (1mM), while TAPI-I (50mM) had little effect.
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full-length human BCMA plus either wt PS1, or its catalytically
inactive mutant D385A (ref. 22). Cleavage of mBCMA and
release of sBCMA occurred only in the presence of an active
g-secretase complex as seen with FACS, ELISA and western blot
analysis (Fig. 4a–d). To date, g-secretase is known to cleave only
membrane proteins after a previous cut by other proteases16,17.
This was in conflict with our mass spectrometry analysis
indicating that sBCMA had an intact N terminus (Fig. 2e).
Therefore, we used an additional experimental approach to assure
that g-secretase cleaved mBCMA without prior N-terminal
trimming. We transfected a cDNA construct coding for BCMA
tagged with an N-terminal FLAG. Using an ELISA with anti-
FLAG for coating and anti-BCMA for detection, we found the
release of sBCMA with N-terminal FLAG, which was blocked by
the g-secretase inhibitor DAPT (Fig. 5a,b). This provides further
evidence that g-secretase sheds BCMA without prior N-terminal
trimming by another protease.
To analyse the importance of the length of the short
extracellular domain of BCMA (54 aa) for its direct cleavage by
g-secretase, we doubled its extracellular part (variant BCMA–
BCMA) with an extracellular part of 108 aa. We transfected wild-
type BCMA and BCMA–BCMA in HEK293T cells. While the
g-secretase inhibitor DAPT strongly enhanced the surface
expression of transfected wild-type mBCMA, DAPT had little
or no effect on surface expression of BCMA–BCMA (Fig. 5c,d).
Similarly, when we measured the released sBCMA, we found that
DAPT strongly decreased its release from wild-type BCMA, but
had little effect on shedding of BCMA–BCMA (Fig. 5e). Thus, the
short extracellular domain of BCMA facilitates its direct cleavage
by g-secretase.
c-secretase regulates NF-jB-mediated activation via BCMA.
The reduced surface expression of mBCMA mediated by
g-secretase was linked to a reduced binding of APRIL
(Supplementary Fig. 2c). To analyse whether the DAPT-increased
mBCMA expression was accompanied by enhanced
cellular responsiveness, we analysed NF-kB activation in
BCMA-transfected HEK cells. DAPT increased BCMA-mediated
NF-kB activation induced via APRIL (Fig. 6a) and also via
BAFF (Fig. 6b).
sBCMA acts as a decoy inhibiting APRIL in vitro. We found
that human sBCMA bound APRIL, but not BAFF (Fig. 7a). This is
different to mBCMA, which binds both APRIL and BAFF3,23. We
found that the naturally occurring sBCMA differed from
recombinant BCMA-Fc, which bound APRIL and BAFF;
however, binding to APRIL was stronger (Fig. 7a). Differences
between sBCMA and BCMA-Fc were also seen in NF-kB reporter
assays: in HEK cells transfected with BCMA, APRIL-mediated
NF-kB activation was blocked by both sBCMA and BCMA-Fc,
while BAFF-mediated activation via mBCMA was suppressed only
by BCMA-Fc, but not by sBCMA (Fig. 7b). Since APRIL can signal
via mBCMA and TACI3, we transfected HEK cells also with TACI.
These experiments showed that sBCMA inhibited APRIL, but not
BAFF-mediated signalling via TACI (Supplementary Fig. 4).
Further, sBCMA limited APRIL-mediated survival of activated
primary B cells (Fig. 7c). The effects of BCMA shedding by
g-secretase are summarized in a diagram (Fig. 7d).
c-secretase regulates plasma cells and B cells in vivo. We tested
whether cleavage of mBCMA by g-secretase occurred also in vivo
using two different mouse models. First, we immunized mice with
ovalbumin (OVA)þ lipopolysaccharide (LPS) to induce a
T-dependent immune response and plasma cell differentiation.
Treatment 9 days later with the g-secretase inhibitor LY-411575-I
for 1 day enhanced surface expression of mBCMA in CD138þ
plasma cells in the spleen (Fig. 8a) and bone marrow
(Supplementary Fig. 5). In the absence of a g-secretase inhibitor,
mBCMA was hardly detectable at all on the surface of murine
plasma cells, in line with previous observations8. Second, we used
an SLE model in NZB/W mice, in which germinal centres develop
spontaneously24,25. In addition here, 1 day of treatment with the
g-secretase inhibitor LY-411575-I enhanced surface expression of
BCMA on plasma cells in the spleen and bone marrow (Fig. 8b).
To distinguish between short-lived and long-lived plasma cells,
mice were fed bromodeoxyuridine (BrdU). We found that
inhibition of g-secretase for 1 day enhanced mBCMA both on
BrdUþ plasma cells (designated also as short-lived plasmablasts)
and on BrdU plasma cells (designated also as long-lived plasma
cells) in the bone marrow and spleen (Fig.8b).
We then analysed the effects of extended application of the
g-secretase inhibitor and treated NZB/W mice for 7 days. This
resulted again in enhanced expression of mBCMA on BrdUþ
and BrdU plasma cells in the bone marrow and spleen (Fig. 8c).
This prolonged treatment period enhanced the number of plasma
cells in the bone marrow, but not in the spleen (Fig. 8d). In the
spleen, the absolute number of BrdUþ plasma cells per organ
decreased, but not their relative number (Fig. 8d,e). In the bone
marrow, treatment with the g-secretase inhibitor increased both
the absolute and also the relative number of plasma cells
(Fig. 8d,e).
The increase in plasma cell number in the bone marrow after




































































































Figure 4 | Release of sBCMA requires active presenilin. (a–d) Presenilin-
deficient MEF cells (PS / ) were transduced with human BCMA
(PS / BCMA) and then with wild-type PS1 (PS / BCMA PS1) or
with a catalytically inactive mutant (PS / BCMA PS1-D385A). BCMA
surface expression (a,b) and sBCMA release (d) were determined. In a, a
representative experiment is shown; in b,d, mean±s.e.m. of four independent
experiments is given (respectively, P¼0.0313 and P¼0.0033, paired t-test).
(c) Cells used in a,b,d were analysed by immunoblotting for expression of
full-length PS1 (PS1holo), for autoendoproteolysis of PS1 generating a
C-terminal fragment (PS1CTF) reflecting an active state of the g-secretase, for
maturation of nicastrin (NCT) and for full-length BCMA (mBCMA).
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mBCMA on plasma cells (Fig. 8, Supplementary Fig. 4) or on
decoy effects of sBCMA, which we observed in vitro (Fig. 7b,c).
To analyse possible immunoregulatory effects of the shed sBCMA
in vivo, we produced recombinant sBCMA and applied it
systemically. We prepared sBCMA as a fusion protein with
a1-antitrypsin (AT; Supplementary Fig. 6a) to increase its
molecular weight and therefore its half live in vivo.
The monomeric structure of sBCMA-AT was confirmed using
gel filtration (Supplementary Fig. 6b). Having shown that
recombinant sBCMA-AT blocked APRIL-mediated NF-kB
activation in vitro (Supplementary Fig. 6c), we gave sBCMA-AT
three times a week for 4 weeks to NZB/W mice, which had
been immunized with OVA before. The applied amount of
sBCMA-AT corresponded to the dose previously used for
BCMA-Fc26,27. Nevertheless, under these conditions sBCMA-
AT did not modulate the total number of plasma cells, the
number of OVA-specific plasma cells or the amount of
circulating IgG, IgA and IgM (Supplementary Fig. 6d–f).
Notably, inhibition of g-secretase had additional effects on
B cells not expressing BCMA. Short-term treatment with
the g-secretase inhibitor reduced GC B cells (defined as
CD38intFashigh) in the spleen as seen in our immunization model
(Supplementary Fig. 7a,b). Moreover, after 7 days of treatment,
NZB/W mice had fewer B cells in the spleen and bone marrow
and showed a striking reduction of pre-B cells in their bone
marrow (Supplementary Fig. 7c).
Discussion
We report that g-secretase directly sheds mBCMA and regulates
the number of plasma cells in the bone marrow. Further, the
released sBCMA reflects B-cell activation in human autoimmu-
nity, namely compartmentalized Ig production in MS and disease
activity in SLE.
When B cells are activated and differentiated towards
Ig-secreting cells, they start to express mBCMA5,6, which is
then shed by g-secretase as we show here. Our experiments with
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Figure 5 | Release of sBCMA occurs without prior N-terminal trimming and is facilitated by the short extracellular domain of BCMA. (a,b) HeLa cells
were transfected with plasmids coding for full-length human BCMA or BCMA with an N-terminal FLAG and then cultured with increasing amounts of the
g-secretase inhibitor DAPT (0.02, 0.1 and 0.5 mM). Twenty-four hours after transfection supernatants were harvested and the released sBCMA was
analysed using ELISA. In (a), ELISA wells were coated with anti-BCMA, and in (b) with anti-FLAG or a control IgG (anti-myelin oligodendrocyte
glycoprotein (MOG) 8.18 C5), both were developed with anti-BCMA. Schemes of the ELISAs are shown on the right. Combined data of two independent
experiments (mean±s.e.m.). (c–e) Human BCMA wild type (wt) or BCMA–BCMA with a doubled extracellular domain of BCMA were transfected into
HEK293T cells. (c,d) Surface expression of BCMA was determined in the absence or presence of the g-secretase inhibitor DAPT (1mM). (d) The combined
data of three experiments (P¼0.0049, **Po0.01, unpaired t-test). (e) The effect of DAPT on the released sBCMA after transfection with BCMA wt or















































Figure 6 | c-secretase regulates BCMA-mediated NF-jB activation.
(a,b) HEK293T cells were transfected with full-length human BCMA or an
empty vector. DAPT, APRIL (a) or BAFF (b) were added, and NF-kB
activation was determined. Combined data of three independent
experiments (mean±s.e.m., *Po0.05, paired t-test).
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transfectants indicate that BCMA shedding by g-secretase is a
consequence of surface expression of mBCMA; it does not require
additional activation or ligand binding; however, we cannot
exclude that this shedding can be further enhanced by yet
unknown mechanisms. g-secretase is ubiquitously expressed16,17
and accessibility of its transmembranous substrates is largely
regulated by the length of their extracellular part. While
membrane proteins with an extracellular domain exceeding 100
aa are not efficiently cleaved, extracellular domains of B50 aa
permit effective cleavage28,29. g-secretase may remove protein
stubs for further degradation and was hence called ‘proteasome of
the membrane’16, although this notion is controversially
discussed29. Probably due to these length restrictions, it has
been a unifying feature of all substrates of g-secretase (for
example, NOTCH and APP) that they become accessible to
cleavage only after their extracellular domain has been trimmed
by another protease16,17. We now show that g-secretase can
cleave mBCMA directly and that prolonging its extracellular part
greatly reduced this cleavage. Thus, constitutive cleavage of
mBCMA by g-secretase is facilitated by its short (54 aa)
extracellular domain. Further we found that g-secretase reduced
BAFF and APRIL-mediated NF-kB activation via BCMA in vitro.
To get insight into the in vivo relevance of mBCMA shedding
by g-secretase, we used an immunization protocol and an SLE
model with spontaneous formation of germinal centres and
plasma cells24,25. We found that inhibition of g-secretase
enhances mBCMA on plasma cells in the bone marrow and

































































































































B-cell activation and survivalB-cell activation and survival
sBCMA BCMA-Fc sBCMA BCMA-Fc
BCMAPlasmid
Figure 7 | sBCMA is a decoy for APRIL in vitro. (a) A scheme of the ELISA is shown on the left; it detects BCMA–APRIL–FLAG (left panel) or
BCMA–BAFF–FLAG (right panel) complexes, but neither BCMA nor APRIL–FLAG nor BAFF–FLAG alone alone (*Po0.05, paired t-test). sBCMA was
derived from the supernatant of plasmacytoma cultured under serum-free conditions. Combined data of three independent experiments (mean±s.e.m.).
(b) HEK293T cells were transfected with human BCMA and activated with APRIL (left panel) or BAFF (right panel). sBCMA (50 and 200 ng ml 1) was
applied as indicated. sBCMA and control supernatant were obtained as mentioned above. BCMA-Fc (50 and 200 ng ml 1) was used as a positive control.
Combined data of three independent experiments (mean±s.e.m., *Po0.05; **Po0.01 paired test). (c) Murine B cells were activated via anti-IgM and
cultured for 2 days with APRIL in the presence or absence of sBCMA (200 and 400 ng ml 1). APRIL-induced survival was calculated as described in the
Methods section. sBCMA was obtained from supernatant from HEK293T cells transfected with full-length BCMA (black bars). Control supernatant was
obtained after transfection with an empty vector (white bars). sBCMA significantly inhibited APRIL-mediated survival (***Po0.001 and **Po0.01, paired
t-test). Combined data of six independent experiments (mean±s.e.m.). (d) Illustration of the consequences of sBCMA shedding by g-secretase: left: an
active g-secretase cleaves mBCMA. This reduces the number of membrane-bound BCMA molecules and releases sBCMA, which binds its ligand APRIL
functioning as a decoy. Right: g-secretase inhibitors (GSIs) result in elevated mBCMA on the surface and increased APRIL-mediated activation and survival.
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cells indicating that both short-lived plasmablasts and long-lived
plasma cells are regulated. Application of a g-secretase inhibitor
in vivo for 7 days enhanced the number of plasma cells in the
bone marrow, but not in the spleen. We assume that the
enhanced number of plasma cells in the bone marrow after
g-secretase inhibition is at least partly caused by an enhanced
presence of mBCMA, since mBCMA mediates the induction of
the survival protein Mcl-1 in bone marrow plasma cells7,8. The
differential effect of g-secretase inhibition on the plasma cell
number in the spleen and bone marrow might be explained by the
previous observation that BCMA induced high expression of
Mcl-1 in bone marrow but not in spleen plasma cells8. In
addition, BCMA / mice had reduced plasma cell numbers in
the bone marrow, but not in the spleen8.
Reduction of plasma cell number in the bone marrow by
g-secretase could be based on reducing membrane-bound
mBCMA or, alternatively, on the shed decoy sBCMA. We tested
the decoy potential of sBCMA in vitro and in vivo. In vitro,
sBCMA blocked APRIL, but had little or no effect on BAFF, while
BCMA-Fc inhibited both BAFF and APRIL similarly. The
functional features we observed for sBCMA are similar to those
described previously for human recombinant monomeric BCMA,
which bound and blocked only APRIL, while recombinant
human dimeric BCMA-Fc bound both APRIL and BAFF30.
Binding assays revealed an avidity contribution of dimeric versus
monomeric recombinant BCMA, which resulted in a41,000-fold
increase in apparent affinity of BCMA binding to BAFF30. To get
insight into the immunoregulatory capacity of sBCMA in vivo, we
produced a recombinant variant of sBCMA (sBCMA-AT).
sBCMA-AT blocked APRIL-mediated NF-kB activation
in vitro, but did, in contrast to what was observed with BCMA-
Fc previously26, not affect plasma cell numbers in the bone
marrow when given systemically. Murine bone marrow plasma
cells receive survival signals either via BAFF or APRIL10, which is
consistent with our finding that sBCMA, which blocks mainly
APRIL, has no effect on plasma cell numbers in the bone marrow.
Together, we conclude that the effect of BCMA shedding on the
plasma cell number in the bone marrow is largely based on the
reduction of surface mBCMA. This would not exclude a function
of sBCMA, especially in a mucosal environment as a decoy for
APRIL, since APRIL-deficient mice had a reduced IgA response
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Figure 8 | c-secretase regulates plasma cells in mice. (a) Immunized (OVA–LPS in alum) C57/BL6 mice were treated with the g-secretase inhibitor
LY-411575-I or vehicle, and the surface display of BCMA in splenocytes was measured using flow cytometry 1 day later. BCMA expression on gated
B220þCD138þ cells is shown, a representative example (left) and compiled data from all 17 analysed animals (mean, ***Po0.001, unpaired t-test; right).
The black symbols on the right indicate the samples shown on the left. Closed histograms indicate isotype controls. (b) NZB/W mice pretreated with BrdU
received the g-secretase inhibitor LY-411575-I (red) or vehicle (blue) for 1 day. Surface expression of BCMA on all CD138þ plasma cells (PC) and the
BrdUþ and BrdU PC subgroups in the spleen and bone marrow (BM) was determined using flow cytometry. (c–e) Seven-day treatment of NZB/W mice
with LY-411575-I. (c) BCMA surface expression in the spleen and BM on B220, and BrdUþ and BrdU plasma cells was determined. (d) Absolute number
of plasma cells, BrdUþ and BrdU plasma cells in the spleen and BM. (e) Frequency (% of all cells in the organ) of plasma cells in the spleen and BM.
Compiled data from 10 analysed animals per group (mean; *Po0.05; **Po0.01; ***Po0.001; ****Po0.0001, unpaired t-test).
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We further found that inhibition of g-secretase affected B-cell
subsets in vivo that do not express mBCMA, such as germinal
centre B cells. This might be based on a blockade of NOTCH
pathways, which are known to determine T–B-cell lineage
commitment32, maintenance of marginal zone B cells33,
survival of GC B cells34 and other, not yet identified, substrates
of g-secretase, which also contribute to B-cell activation35.
Together, our data indicate that inhibition of g-secretase
enhances the survival receptor BCMA on plasma cells, increases
the number of plasma cells in the bone marrow and disturbs the
B-cell compartment in the spleen.
Release of membrane receptors is a general regulatory
mechanism of inflammatory responses36. TNFR1 is a
prominent example, and the immunoregulatory features of
TNFR1 shedding were previously explored in vivo with a
knock-in mouse expressing a mutated nonsheddable TNFR1,
which resulted in autoinflammatory features and enhanced
experimental autoimmune encephalitis37. Biochemically, the
release of sBCMA by g-secretase is different from the shedding
of TNFR1, which is performed by the metalloprotease ADAM17
(ref. 36), and of TACI that is shed by ADAM10 (ref. 38).
Does shedding of BCMA also occur in human autoimmune
diseases? We measured sBCMA levels in a compartmentalized
organ-specific autoimmune disease, MS, and in a systemic disease
characterized by general activation of the B-cell compartment,
SLE. A hallmark of MS is B-cell persistence inside the brain
compartment with local Ig production39,40, supported by local
production of BAFF by astrocytes41. We report that sBCMA is
elevated in the CSF in MS and closely correlates with intrathecal
IgG production. Thus, sBCMA in the CSF reflects the local
presence of Ig-secreting cells, which are known to be present in
the MS brain2,39,40,42. This view is also supported by our
observation that reducing inflammation with natalizumab
decreases also sBCMA in the CSF. SLE is characterized by a
systemic hyperactivation of the B-cell compartment43 with
elevated surface expression of mBCMA on circulating immune
cells44. In this disease, we found a systemic elevation of sBCMA,
which is linked to disease activity. Further studies are required to
characterize sBCMA as a potential biomarker of SLE activity.
sBCMA shedding adds to the complexity of the BAFF–APRIL
system. This system is highly relevant in health and disease
and serves as a drug target13,45,46. Release and function of
sBCMA are of direct relevance for clinical trials targeting BAFF,
APRIL and their receptors, which are currently under way13. This
system also affects certain haematological malignancies such as
plasmacytoma3, where sBCMA may also serve as a biomarker47.
Further, since g-secretase is involved not only in Alzheimer’s
disease, but also in autoimmune diseases (including MS), where
g-secretase inhibitors are being tested for therapeutic benefit48,
our findings draw attention to potential side effects of g-secretase
inhibitors related to the shedding of BCMA.
Together, our study yields three main findings. First,
g-secretase directly cleaves mBCMA. Regulation of surface
display of a ligand-binding receptor is a novel function of
g-secretase. Second, g-secretase regulates the number of plasma
cells in the bone marrow. Third, the released sBCMA is a
potential biomarker in human immunological diseases and could
be useful for therapeutic optimization.
Methods
Clinical samples. In a first cohort we obtained plasma and the corresponding CSF
from 37 untreated patients diagnosed with either clinical isolated syndrome
(n¼ 10) or MS (n¼ 27) and from 20 untreated patients with other neurological
diseases; further five CSF samples from neuroborreliosis patients were obtained. In
a second cohort, we analysed CSF pairs from 25 additional MS patients before and
about 1 year after continuous natalizumab therapy. The IgG production within the
brain compartment (intrathecal) was calculated as the IgG index ((CSF IgG/CSF
albumin)/(serum IgG/serum albumin)). We examined longitudinally the sera of 10
patients with MS who were treated with high doses of steroids (1,000 mg per day
methylprednisolone intravenously for 3–5 days) because of a relapse. Samples were
obtained directly before treatment, 3 days and 4 weeks later. We analysed serum
samples from 17 untreated and 22 treated SLE patients. The treated group included
patients treated with glucocorticosteroid, hydroxychloroquine, azathioprine,
cyclophosphamide and mycophenolate mofetyl. Our study included 26 plasma
samples and 29 serum samples of 34 healthy control donors. Detailed data of the
patients included in this study can be found in Supplementary Table 1. This study
was approved by the Ethics Committee of the Ludwig Maximilian University of
Munich. Informed consent was obtained according to the Declaration of Helsinki.
Cytokines and stimuli. In all stimulation and binding assays involving APRIL, we
used mouse MegaAPRIL (EnzoLifeSciences, Farmingdale, NY), which binds both
human and mouse BCMA and TACI; it is fused to FLAG-tag and is referred in this
study as APRIL. BAFF stimulation and binding assays were performed using either
recombinant human BAFF (R&D Systems, Minneapolis, MN) or recombinant
human BAFF–FLAG (EnzoLifeSciences). For stimulation of PBMC and native B
cells, human IL-21 (EBioscience, San Diego, CA), TLR7þ 8 ligand R848 (Sigma-
Aldrich, St Louis, MO) and human IL-2 (R&D Systems) were used. Mouse L cells
stably transfected with human CD40L were used and expression was continuously
monitored.
Antibodies and cell lines. To detect human BCMA the following antibodies were
used: monoclonal antibodies A7D12.2 (IgG2b) and C12A3.2 (IgG1) (kindly pro-
vided by BiogenIdec), and the polyclonal Ab AF193 (R&D Systems). The specificity
of the two monoclonal antibodies to BCMA was confirmed using flow cytometry of
BCMA-transfected MEF cells (Fig. 4a) and HEK cells (Fig. 5c), immunoprecipi-
tation (ip) and subsequent western blot (Fig. 2f,g) or mass spectrometry (Fig. 2h).
Furthermore, an ELISA using A7D12.2 or C12A3.2 for coating and the polyclonal
goat antibody (AF193; R&D Systems, Minneapolis, MN) for detection with
recombinant BCMA (R&D Systems) as standard detected sBCMA with a sensitivity
of 30 pg ml 1. The following monoclonal antibodies were used for surface
expression analysis using flow cytometry: fluorescein isothiocyanate (FITC)-con-
jugated anti-CD40L (BD PharMingen, San Diego, CA), FITC-conjugated anti-
CD138 (Diaclone, Besançon, France), Cy7-conjugated anti-CD27 and eFluor 450-
conjugated anti-CD38 (EBioscience), Cy7-conjugated anti-CD19 (EBioscience).
For triple staining of BCMA with CD27 and CD38, we used the monoclonal
antibody A7D12.2 and a 647-conjugated goat-anti-mouse IgG2 Ab (Invitrogen Life
Technologies, Carlsbad, CA) along with the directly labelled IgG1 antibodies to
CD38 and CD27 mentioned above. For the detection of APP-derived C99, the
monoclonal antibody 4G8, SIG-39220 (Covance, Emeryville, CA) was used.
Single-cell suspensions were prepared from the bone marrow (femur and tibia)
and spleen. Mouse BCMA was detected using flow cytometry with biotin-
conjugated anti-mouse BCMA (BAF 593; R&D Systems) along with eFluor450- or
PE-Cy7-conjugated streptavidin. BrdU staining of plasma cells was performed
using a BrdU Flow Kit (BD Biosciences, San Jose, CA) according to the
manufacturer’s protocol. The detection of plasma cells was carried out with anti-
CD138-PE (clone 281-2; BD Biosciences) for surface staining and anti-kappa-
Pacific Orange (clone 187.1; DRFZ) for intracellular staining. B and T cells were
identified with the following anti-mouse antibodies: CD21 (clone 7E9, BioLegend,
CA, USA), CD23 (clone B3B4, BioLegend), CD24 (clone M1/69, BD Biosciences),
CD93 (clone AA4.1, BioLegend), CD95 (clone Jo2, BD Biosciences), CD117 (clone
2B8, BD Biosciences), IgM (clone RMM-1, BioLegend), B220 (clone RA3-6B2,
DRFZ), IgD (clone 11-26c, DRFZ), GL-7 (clone GL-7, DRFZ), CD4 (clone GK1.5,
DRFZ) and CD8 (clone 53-6.7, BioLegend). Identification of B-cell subsets in the
spleen: B1: IgMhighCD21low/CD23CD93 . Follicular B cells: IgMþCD21þ
CD23þCD93 . Marginal zone B cells: IgMhighCD21þCD23CD93 . GL-7þ :
GL-7þ IgD . Identification of B-cell subsets in the bone marrow: pro-B cells:
B220þCD93þCD117þ . pre-B cells: B220þCD24þ IgM IgD . Immature B
cells: B220þCD24þ IgMþ IgD . Mature B cells: B220þCD24low/ IgMþ IgDþ .
Cytometric analysis was performed using a FACSCanto II cytometer
(BD Biosciences) and data were analysed with the FlowJo software (Tree Star Inc.).
Source and working concentration of antibodies used are listed in Supplementary
Table 2.
MEFs deficient for presenilin 1 (PS1) and presenilin 2 (PS2) (PS / ) were
kindly provided by Dr Bart De Strooper (Leuven, Belgium)21; PS / status was
monitored using western blot analysis with the antibody PSEN1 (Epitomics,
Burlingame, CA). The plasmacytoma cell line JK-6L (ref. 49) was kindly provided
by Dr Silke Meister (Erlangen, Germany); expression of the surface markers CD138
and BCMA was controlled. This cell line was cultured in RPMI supplemented with
10% FCS and in serum-free conditions (Hybridoma 6 direkt from Bio&SELL,
Nürnberg, Germany). Further, HeLa and HEK293T were applied in transfection
experiments.
Detection of BCMA and its ligands APRIL and BAFF. Surface expression of
human BCMA was determined using flow cytometry on FACS Verse (BD Bios-
ciences) using C12A3.2 or A7D12.2 and appropriate secondary antibodies. To
measure human sBCMA in the plasma, CSF or cell culture supernatants, a
sandwich ELISA with polyclonal goat antibodies was used (BCMA/TNFRSF17
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ELISA Duoset; R&D Systems). To detect sBCMA with an N-terminal FLAG, the
monoclonal antibody anti-FLAG M2 antibody (Sigma-Aldrich) was used for
coating and the biotinylated polyclonal goat-anti-BCMA antibody (R&D Systems)
for detection. As a control the anti-myelin oligodendrocyte glycoprotein mono-
clonal antibody 8.18C5 was used for coating. To measure APRIL in CSF, a sand-
wich ELISA was used (Bender MedSystem, Vienna, Austria). BAFF levels in the
serum were measured using the Quantokine human BAFF Elisa kit (R&D Systems).
To assess binding of sBCMA or BCMA-Fc (kindly provided by Biogen Idec) to
APRIL and BAFF, an ELISA was used with the anti-FLAG M2 monoclonal
antibody (Sigma-Aldrich) for coating to bind FLAG-tagged APRIL or
BAFF–FLAG. Then, sBCMA from supernatant of plasmacytoma cells, which was
concentrated with Amicon Ultra 3 K devices (Merck Millipore Ltd., Ireland), or
BCMA-Fc was added and incubated for 2 h at room temperature. BCMA was
detected as described above.
Immunoprecipitation and western blot analysis. Immunoprecipitation of
BCMA was performed with the monoclonal antibody A7D12.2, the monoclonal
antibody C12A3.2 or a polyclonal goat antibody (AF193; R&D Systems). These
antibodies were coupled to Dynabeads Protein G (Life Technologies, AS, Oslo) and
cross-linked with bis-sulfosuccinimidyl-suberate3 (Pierce Chemical Co., Rockford,
IL). After successive incubation with either supernatant of plasmacytoma cells or
serum, we eluted with glycine or SDS loading buffer (NuPAGE LDS Sample Buffer,
Life Technologies). Cells were lysed at 4 C for 1 h in NP-40 lysis buffer (150 mM
NaCl, 50 mM Tris pH 7.5, 1% Nonidet P-40) containing complete protease
inhibitor cocktail (Roche Applied Science, Penzberg, Germany). BCMA was
detected by western blot analysis with the monoclonal antibody C12A3.2. Blots
were developed using the mouse true blot goat anti-mouse IgG-HRP system
(EBioscience) and enhanced chemiluminescence (ECL). Expression and
endoproteolysis of PS1 was analysed by immunoblotting of cell lysates with the
antibody PSEN1 (Epitomics); maturation of nicastrin (NCT) was evaluated by
immunoblotting with the antibody N1660 (Sigma-Aldrich).
Mass spectrometry and sample preparation. sBCMA was purified by immu-
noprecipitation and obtained by acidic elution. The eluate was then desalted and
concentrated using StageTips, C18, microcolumns (Thermo Scientific, Bremen,
Germany). Then two approaches were followed. (A) The material was digested in
solution by trypsin or chymotrypsin and analysed using mass spectrometry (LTQ
Orbitrap XL) as described before50. (B) The immunoprecipitated material was
separated via an SDS gel, silver-stained and the band corresponding to BCMA as
detected using western blot analysis was excised and analysed using mass
spectrometry (LTQ Orbitrap XL).
Cell culture and gene transfer. Two experimental systems were used to differ-
entiate primary human B cells to Ig-secreting cells. First, B cells were positively
selected from PBMC with CD19 MACS beads (Miltenyi Biotec, Bergisch Gladbach,
Germany) and differentiated into IgG-secreting cells by coculture with CD40L-
transfected mouse L cells and recombinant human IL-21 (50 ng ml 1). Further
separation of CD19þCD38þ and CD19þCD38 cells was performed using
CD38 MACS beads. Second, PBMC were stimulated with the TLR7þ 8 ligand
R848 (2.5 mg ml 1) and IL-2 (1,000 IU ml 1) as described19. Secreted IgG was
quantified by ELISA (Mabtech, Nacks Strand, Sweden). To analyse the effects of
DAPT and TAPI-1, these Ig-secreting cells were washed after 7 days and cultured
for another 16 h with either inhibitor.
To measure APRIL-induced survival, mouse B cells (magnetically isolated from
spleen using the EasySep Mouse B Cell Isolation Kit (Stemcell Technologie,
Vancouver, Canada)) were cultured in 96-well microtiter plates, which were
precoated with anti-IgM (5mg ml 1). APRIL (100 ng ml 1) was added for 48 h and
cross-linked with anti-FLAG monoclonal antibody (Sigma-Aldrich). Supernatants
generated by HEK293T cells that had been transfected with full-length BCMA
(OriGene Technologies, Inc., Rockville) or an empty control vector and therefore
either contained sBCMA or did not, were added at a final sBCMA concentration of
200 ng ml 1 and 400 ng ml 1. Cell survival was quantified by flow cytometry using
TO-PROs-3 Iodide viability dye (Invitrogen Life Technologies) and APRIL-induced
survival was calculated as followed: 100 x [(cell survival in presence of APRIL—cell
survival without APRIL)/cell survival without APRIL].
To obtain BCMA with an N-terminal FLAG-tag, full-length human BCMA
(h184) from a human BCMA cDNA clone (OriGene Technologies) was first
amplified by PCR. The PCR fragment was then digested and ligated into the
pCMV6-AN-DDK vector (OriGene Technologies). This construct does not contain
a signal peptide, since the native BCMA also does not contain one23. To obtain a
BCMA variant with a prolonged extracellular part, the extracellular part of human
BCMA was amplified by PCR, digested and ligated at the N-terminal end of full-
length human BCMA clone (OriGene Technologies). We thereby doubled the
extracellular part, and called the new construct BCMA–BCMA. The plasmid
peak12-SP-C99 expresses the C-terminal 99 amino acids of APP together with the
APP signal peptide. C99 is a direct substrate for g-secretase51. Peak12-SP-C99 was
obtained by cloning SP-C99 from the pCEP4 vector into the peak12 plasmid51.
HEK or HeLa cells were transfected with 200 ng of respective expression plasmids
using lipofectamine 2,000 (Invitrogen Life Technologies).
Using lentiviral gene transduction, MEF deficient for PS1 and PS2 (PS / )
were stably transduced with full-length human BCMA and then stably transduced
with either wt PS1 or a catalytically inactive D385A mutant of PS1 (22).
Enzyme inhibitors. We used the following g-secretase inhibitors: DAPT
(Calbiochem Merck, Darmstadt, Germany), L685,458 (R&D Systems), RO49290
(Selleckchem, Houston, TX, USA) and the steroisomer SSR of LY-411575, referred
as LY-411575-I (Sigma-Aldrich). This steroisomer of the g-secretase inhibitor
LY-411575 is also a g-secretase inhibitor as observed with the APP fragment C99
and BCMA as substrates (Supplementary Figures 3 and 8). Metalloproteases were
inhibited with TAPI-1 (EMD Chemicals/Calbiochem, Inc. Gibbstown US).
Corresponding concentrations of DMSO (Sigma-Aldrich) were used as vehicle
controls. Reduced BCMA shedding was observed at a vehicle concentration of 0.5%
DMSO, which corresponds to 50 mM TAPI-1.
NF-jB reporter assay. To measure NF-kB activation, HEK293T cells were
transiently transfected with a plasmid containing a firefly luciferase reporter gene
under the control of an NF-kB transcriptional response element, a plasmid with a
Renilla reniformis luciferase reporter gene for normalization and the indicated
amounts of expression or control plasmids using Lipofectamine 2000 (Invitrogen
Life Technologies). We used human BCMA or human TACI for transfection. To
determine the effect of g-secretase inhibition on NF-kB activation, cells transfected
with BCMA were treated with DAPT or a solvent control and 6 h later stimulated
with APRIL or BAFF. To analyse a possible decoy function, DAPT along with
BAFF or APRIL were added to BCMA-Fc or supernatants generated by HEK293T
cells that had been transfected with full-length BCMA or an empty control vector
as described above. These supernatants were incubated at 37 C for 30 min and
then added to BCMA or TACI-transfected and DAPT-treated cells used for the
reporter assay. 16 h after stimulation cells were harvested and cell lysates were
prepared using passive lysis buffer (Promega, Madison, WI, USA) and the reporter
gene activity was measured using firefly luciferase substrate (Biozym, Hameln,
Germany) and renilla luciferase substrate (Promega) respectively.
Flow cytometry sorting and quantitative RT-PCR. Human B cells were positively
selected from PBMC with CD19 MACS beads (Miltenyi Biotec) and differentiated
into IgG-secreting cells by coculture with CD40L-transfected mouse L cells and
recombinant human IL-21 as described above. CD27þ þCD38þ and CD38 cells
were sorted using the BD FACS Aria cell sorting system (Becton Dickinson,
Heidelberg, Germany). For quantitative PCR analysis, RNA was isolated using the
RNeasy Micro Kit (Qiagen, Hilden, Germany) and cDNA was generated using the
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Darmstadt,
Germany). To detect BCMA transcripts, primer and probes were used as
published41. As housekeeping gene Cyclophilin A (PPIA) was used and detected
with the primer and probes 43263416E from Applied Biosystems. Reactions were
carried out in duplicate using TaqMan assays in combination with the TaqMan
PCR Core Reagent Kit (Applied Biosystems). Samples were run in MicroAmp
Optical 96-well reaction plates in a 7900HT Fast Real-Time PCR System (Applied
Biosystems). Data were analysed using the SDSv2.3 software (Applied Biosystems).
sBCMA-AT fusion protein. The cDNA of the extracellular part of mouse BCMA
(sBCMA) was synthesized using the Integrated DNA Technology with a BspEI and
an Age I site at the 50 and 30 ends, respectively, and fused to the 30 end of human
AT in the expression vector pTT5 (ref. 52). The resulting fusion between AT and
sBCMA (extracellular residues from position 2 to 49 lacking the first methionine) is
separated by a short flexible peptide linker TGSGSGA and terminates with
hexahistidine tag to facilitate purification. The free cysteine residue on the surface
of wild-type AT was replaced by a serine residue to prevent dimerization in
oxidizing environments. The fusion protein was expressed in HEK293-EBNA cells
as described previously52. MW was determined with standard Coomassie gel and
the size was analysed using gel filtration with the Superose 12 HR 10/30 gel
filtration column (Amersham/GE Healthcare Life Sciences, Freiburg, Germany) on
a fast protein liquid chromatography column (FPLC). Function of sBCMA-AT was
tested using NF-kB reporter assays.
c-secretase inhibitor and recombinant sBCMA-AT in mice. Two different
mouse models were applied. First, 2-month-old C57/BL6 mice were immunized
intraperitoneally with 100 mg OVA and 10mg LPS in alum (a protocol based on ref.
53) and killed 10 days later. Immunized mice received an intraperitoneal dose
(10 mg kg 1) of LY-411575-I on day 9, followed by another dose 6 h before being
killed. Second, female 16- to 18-week NZB/W F1 mice were bred at the animal
facility of the German Rheumatism Research Center Berlin (DRFZ) under defined,
pathogen-free conditions. To distinguish between short-lived and long-lived
plasma cells, we fed the mice BrdU (Sigma-Aldrich, 1 mg ml 1) with 1% glucose in
drinking water for 2 weeks. One week after the start of BrdU feeding, mice were
treated daily with the g-secretase inhibitor LY-411575-I intraperitoneally at a dose
of 10 mg kg 1 for 7 days. Finally, 2-month-old NZB/W mice were immunized
intraperitoneally with OVA (100 mg per mouse and alum (Thermo) as adjuvant) as
described54 and boosted at 3 months. At 4 months, mice were treated for four
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consecutive weeks intraperitoneally with recombinant sBCMA-AT fusion protein
(200 mg three times a week). The concentration of this fusion protein in the serum
of the injected mice was determined with an AT ELISA, which is specific for
human AT (ab189579 from Abcam, Cambridge, UK). Single-cell suspensions were
prepared from the spleen and bone marrow (femur and tibia) as described before.
Cells were first incubated with anti-CD138-PE and then fixed with Cytofix/
Cytoperm buffer (BD Bioscience) for 30 min. Intracellular Ig kappa light chain was
detected by anti-kappa-Pacific Orange and OVA-specific antibodies were detected
by intracellular OVA conjugated with FITC.
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